Dual-target CAR-NK cell product

BIOLOGICAL2 trials

Sponsors

Beijing Biotech

Conditions

Epithelial Ovarian CancerFallopian Tube CarcinomaPrimary Peritoneal CarcinomaRecurrent or Refractory Disease After Standard Therapies

Phase 1

Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)

RecruitingNCT07480954

Beijing BiotechEpithelial Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma +1

Start: 2026-02-04End: 2028-05-17Target: 36Updated: 2026-03-18

Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2

RecruitingNCT07617753

Beijing BiotechEpithelial Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma +1

Start: 2026-03-02End: 2028-03-17Target: 36Updated: 2026-06-01